Breast cancer is a complex disease encompassing multiple tumor entities, each
characterized by distinct morphology, behavior and clinical implications. Besides estrogen …

Breast cancer is a heterogeneous complex of diseases, a spectrum of many subtypes with
distinct biological features that lead to differences in response patterns to various treatment …

Single-cell transcriptome profiling of tumour tissue isolates allows the characterization of
heterogeneous tumour cells along with neighbouring stromal and immune cells. Here we …

Purpose Immune checkpoint inhibition has been demonstrated to be an effective anticancer
strategy. Several lines of evidence support the study of immunotherapy in triple-negative …

Purpose Studies suggest that a subset of patients with triple-negative breast cancer (TNBC)
have tumors that express the androgen receptor (AR) and may benefit from an AR inhibitor …

Triple negative breast cancer (TNBC) is a subtype of breast tumor lacking hormone
receptors expression and HER2 gene amplification and represents 24% of newly diagnosed …

Triple-negative breast cancer (TNBC) accounts for 15% to 20% of breast cancer cases and
is characterized by the absence of estrogen, progesterone, and human epidermal growth …

Triple-negative breast cancer (TNBC), which accounts for 15–20% of all breast cancers,
does not express estrogen receptor (ER) or progesterone receptor (PR) and lacks human …

Intratumor heterogeneity is a major clinical problem because tumor cell subtypes display
variable sensitivity to therapeutics and may play different roles in progression. We previously …

Purpose The identification of patients with metastatic triple-negative breast cancer (mTNBC)
who are expected to benefit from platinum-based chemotherapy is of interest. We conducted …